{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-276891","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.894396+00:00","generated_at":"2026-06-22T08:51:51.509722+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Q3 2022 XPOVIO sales up 20% YoY; net loss narrows to $0.45/share; guidance reaffirmed","bullets":["Total revenue $36.1M (-4% YoY); XPOVIO net product revenue $32.0M (+20% YoY).","Net loss $36.3M ($0.45 per share) vs $51.8M ($0.69) in Q3 2021; cash $150.1M.","Reaffirmed FY2022 guidance: total revenue $155-165M, XPOVIO $120-130M.","Initiated Phase 3 selinexor maintenance in TP53 wild-type endometrial cancer; topline 2024.","Phase 1 selinexor+ruxolitinib in myelofibrosis shows SVR35 at 79% at week 12; updated data at ASH."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-276891","json":"https://secwatch.observer/filing/0001193125-22-276891.json","markdown":"https://secwatch.observer/filing/0001193125-22-276891.md","text":"https://secwatch.observer/filing/0001193125-22-276891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522276891/0001193125-22-276891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522276891/d403188d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:51:51.509722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"596a379afcb7f3aec3c4c1e3f726ff0964ba16db","claim":"Karyopharm Therapeutics Inc. reported the quarter ended September 30, 2022 results: revenue $36.1 Million. Guidance reaffirmed.","evidence_excerpt":"Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress – Achieved Third Quarter 2022 Total Revenue of $36.1 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522276891/0001193125-22-276891-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$36.1 Million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"aaab23fc3eb5cd777f5bf2b52587f5104f77666b","claim":"Karyopharm Therapeutics Inc. reported full year 2022 results: revenue $155 Million to $165 Million. Guidance reaffirmed.","evidence_excerpt":"Company Re-Affirms Full Year 2022 XPOVIO Net Product Revenue Guidance of $120 Million to $130 Million, Total Revenue Guidance of $155 Million to $165 Million and Cash Runway into Early 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522276891/0001193125-22-276891-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"$155 Million to $165 Million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}